Chronic Obstructive Pulmonary Disease (COPD) Drug Pipeline Landscape Research Report 2021 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

This Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2021 provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Chronic Obstructive Pulmonary Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Obstructive Pulmonary Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Obstructive Pulmonary Disease.

Chronic Obstructive Pulmonary Disease Emerging Drugs Chapters

This segment of the Chronic Obstructive Pulmonary Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Obstructive Pulmonary Disease Emerging Drugs

Benralizumab: AstraZeneca

Benralizumab (FASENRA) is a monoclonal antibody that binds directly to the IL-5 receptor alpha on eosinophil and attracts natural killer cells to induce rapid and near-complete depletion of eosinophil via apoptosis (programmed cell death). The drug is approved by the US FDA for asthma and is currently being developed for other respiratory and immunological disorders such as COPD, atopic dermatitis, and others.

The drug was earlier in GALATHEA and TERRANOVA trials (randomized, double-blinded, placebo-controlled, parallel-group trials that assessed the safety and efficacy of Fasenra 30mg and 100mg for preventing COPD exacerbations). At present, the drug is in RESOLUTE (Phase III trial) to evaluate its efficacy and safety.

MV130: Inmunotek S.L.

MV130 (BACTEK) is a bacterial mucosal vaccine or a bacterial polyvalent vaccine in a spray that is administered sublingually to treat recurrent respiratory tract infections in children and adults. MV130 plays a relevant role in modulating the functional activity of the innate and adaptive immune response by stimulating dendritic cells, which are part of innate immunity. A Phase III clinical trial is evaluating MV130 in patients with COPD. At present, the trial is ongoing in Spain.

SB-240563: GlaxoSmithKline

SB-240563 (mepolizumab) is a humanized monoclonal antibody that blocks human interleukin 5 (hIL-5) from binding to its receptor. Initial clinical studies investigated the safety and efficacy of SB-240563 for the treatment of asthma and atopic dermatitis (AD). SB-240563 reduced peripheral and tissue eosinophils in patients with asthma and healthy volunteers. Currently, it is in the Phase III stage of the clinical trials.

SAR440340: Sanofi/Regeneron

SAR440340 (Itepekimab) is a humanized IgG4P monoclonal antibody that blocks human interleukin 33 (hIL-33) from binding to its receptor. IL-33 is an epithelial cytokine that initiates and amplifies innate and adaptive type 2 and 1 inflammatory pathways in response to epithelial insults due to exposure to allergens, viruses, cigarette smoke, and pollutants.

SAR440340 was invented using Regeneron's proprietary VelocImmune technology that yields optimized fully-human antibodies and is being developed jointly by Regeneron and Sanofi as part of a global collaboration agreement.

CHF 6001: Chiesi Farmaceutici S.p.A.

CHF6001 is a novel inhaled phosphodiesterase-4 (PDE-4) inhibitor developed as an extrafine formulation (i.e., with mass median aerodynamic diameter ≤ 2 μm) and low systemic exposure. This allows CHF6001 to reach a therapeutic concentration in the target organ, the lung, with reduced systemic exposure, limiting systemic adverse effects. The drug is administered through a dry powder inhaler (DPI NEXThaler).

YPL 001: Yungjin Pharm. Co., Ltd.

YPL 001 is a drug molecule that belongs to the anti-inflammatory and anti-histamine class of drugs. The drug is being developed for COPD. YPL-001 is a product developed using wild chives, which grow naturally in nature, as a raw material. A Phase II trial was conducted in US hospitals to assess the drug's safety in patients with moderate-to-severe COPD. In Phase I studies, YPL-001 was well tolerated in healthy subjects following single (up to 320 mg) and multiple (up to 240 mg twice daily [BID]) oral doses with no serious adverse events (AEs).

Chronic Obstructive Pulmonary Disease: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Obstructive Pulmonary Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Obstructive Pulmonary Disease

There are approx. 50+ key companies which are developing the therapies for Chronic Obstructive Pulmonary Disease. The companies which have their Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage, i.e. Phase III include, AstraZeneca.

Phases

This report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Chronic Obstructive Pulmonary Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Obstructive Pulmonary Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Obstructive Pulmonary Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Obstructive Pulmonary Disease drugs.

Chronic Obstructive Pulmonary Disease Report Insights

• Chronic Obstructive Pulmonary Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Obstructive Pulmonary Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Companies Mentioned

• 3SBio
• Adamis Pharmaceuticals
• Afimmune
• Astrazeneca
• Boehringer Ingelheim
• Brickell Biotech
• Chiesi Farmaceutici S.p.A.
• CSL Behring; Grifols Biologicals
• Eisai
• EmeraMed
• EpiEndo Pharmaceuticals
• Foresee Pharmaceuticals
• Genentech
• GlaxoSmithKline
• Glenmark Pharmaceuticals
• Idorsia Pharmaceuticals
• Immunotek
• Mereo BioPharma
• Meridigen Biotech Co., Ltd.
• Novartis
• OmniSpirant
• Pulmatrix
• Pulmotect, Inc.
• Quercegen Pharmaceuticals LLC
• Regend Therapeutics
• Rhizen Pharmaceuticals
• Sanofi
• Synairgen
• Tetherex Pharmaceutical
• United Therapeutics Corporation
• Verona Pharma plc
• Vertex Pharmaceuticals
• Yungjin Pharm. Co., Ltd.

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/7vmbdw

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900